Program and Benefits Updates

New Drug Benefit for Transplant Clients

Effective July 1, 2017, Zortess (everolimus) has been approved and added to the Kidney Health Care drug formulary. The immunosuppressant drug is limited to kidney transplant clients. Prior authorization is not required. Information posted July 6, 2017.

Contact KHC by email

Return to Top

Last updated July 7, 2017